Update on m-Tor inhibitors Sirolimus and Everolimus used in Transplantation

Join us for two informative workshops from the 2023 IATDMCT Congress, moderated by Dr. Dario Cattaneo, IATDMCT President

Lecture 1:

Comparative pharmacokinetics of Sirolimus and Everolimus and Latest Recommendations for their Use in Transplantation 

•    Learn about the mechanism of action of m-Tor inhibitors

•    Understand the differences between sirolimus and everolimus related to their current indications, different pharmacokinetics, and metabolism 

•    Hear a discussion around the prerequisites for therapeutic drug monitoring and their target ranges within kidney, heart and liver transplant patients, in addition to the indication in oncology for everolimus.

Lecture 2:

M-Tor Inhibitors in Renal Transplantation in Clinical Practice 

•    Understand how everolimus can be combined with calcineurin inhibitors (cyclosporine or tacrolimus) in kidney transplantation based on the published TRANSFORM study. 

•    Learn about the different selected targets of immunosuppression and the diseases linked to dysregulated mTor signaling. 

•    Hear about the comparison of the classical treatment protocol [mycophenolate (MPA) + standard dose Calcineurin Inhibitors  (sCNI)] with a new protocol [everolimus + reduced dose calcineurin  (rCNI) inhibitor].